Table 1.
Demographic and Baseline Clinical Information
| N participants with PSG and MRI | 632 | 160 | |
|---|---|---|---|
| Age: year, median (IQR) | 61 (52, 69) | 67 (58, 73) | |
| Age: number (%) | |||
| <20 | 0 (0) | 0 (0) | |
| 20–40 | 34 (6) | 2 (1) | |
| 40–60 | 248 (40) | 45 (28) | |
| 60–80 | 306 (49) | 97 (61) | |
| >80 | 34 (6) | 16 (10) | |
| Sex: number (%) | |||
| Female | 342 (55) | 74 (46) | |
| Male | 281 (45) | 86 (54) | |
| Race | |||
| White | 522 (84) | 141 (88) | |
| Black | 43 (7) | 6 (4) | |
| Asian | 8 (1) | 1 (1) | |
| American/Alaska | 3 (0) | 0 (0) | |
| Other | 31 (5) | 8 (5) | |
| Unavailable | 15 (2) | 5 (3) | |
| Ethnicity | |||
| Hispanic | 39 (6) | 7 (4) | |
| Non Hispanic | 550 (88) | 148 (4) | |
| Unavailable | 34 (5) | 5 (3) | |
| N diagnostic PSG studies | 632 (100) | 160 (100) | |
|
Apnea–hypopnea index
(3% desaturations) | |||
| Normal (AHI < 5) | 241 (39) | 65 (41) | |
| Mild (5 ≤ AHI < 15) | 244 (39) | 60 (38) | |
| Moderate (15 ≤ AHI < 30) | 97 (16) | 23 (14) | |
| Severe (30 ≤ AHI) | 41 (7) | 12 (8) | |
| Respiratory disturbance index (RDI, events/hour) (IQR) |
13 (7, 24) | 12 (6, 24) | |
| Limb movement index (events/hour) (IQR) | 13 (4, 38) | 17 (4, 48) | |
| Sleep fragmentation index (IQR) | 4 (3, 6) | 4 (3, 6) | |
| Epworth Sleepiness Scale (IQR) | 7 (4, 11) | 6 (4, 10) | |
| Visit for insomnia evaluation: number (%) | 115 (33) | 27 (29) | |
| Charlson comorbidity index (IQR) | 2 (1, 3) | 2 (1, 3) | |
| Minimal (CCI < 2) | 256 (41) | 61 (40) | |
| Mild (CCI == 2) | 131 (21) | 32 (21) | |
| Moderate (3 ≤ CCI < 5) | 149 (24) | 42 (27) | |
| Severe (5 ≤ CCI) | 88 (14) | 21 (14) | |
| Diagnoses (ICD-10) | N = 583 | ||
| Myocardial infarction | 31 (5) | 6 (4) | |
| Congestive heart failure | 96 (17) | 22 (14) | |
| Peripheral vascular disease | 111 (19) | 32 (21) | |
| Cerebrovascular disease | 171 (29) | 50 (32) | |
| Chronic pulmonary disease | 217 (37) | 43 (28) | |
| Rheumatoid disease | 38 (7) | 7 (5) | |
| Peptic ulcer disease | 15 (3) | 1 (1) | |
| Mild liver disease | 73 (13) | 21 (14) | |
| Diabetes without complications | 150 (26) | 31 (20) | |
| Diabetes with complications | 95 (16) | 21 (14) | |
| Hemiplegia or paraplegia | 7 (1) | 1 (1) | |
| Renal disease | 99 (17) | 28 (18) | |
| Cancer (any malignancy) | 158 (27) | 47 (30) | |
| Moderate or severe liver disease | 1 (0) | 0 (0) | |
| Metastatic solid tumor | 18 (3) | 3 (2) | |
| AIDS/HIV | 3 (1) | 2 (1) | |
| Alcohol abuse | 37 (6) | 18 (12) | |
| Drug abuse | 51 (9) | 17 (11) | |
| Psychoses | 24 (4) | 11 (7) | |
| Depression | 326 (56) | 102 (65) | |
| Diagnoses (chart review) | |||
| Mild cognitive impairment | 71 (11) | 55 (34) | |
| Dementia | 36 (6) | 23 (14) | |
| Time between measurements (years) | |||
| EEG—MRI | 2.2 (1.9) | 1.7 (1.6) | |
| EEG—Neuropsych. | — | 2.1 (2.1) | |
| MRI—Neuropsych. | — | 1.9 (2.1) | |